| Gene Symbol | TGM2 |
| Full Name | Transglutaminase 2 |
| Aliases | TGM2PROTEIN |
| Chromosome | 20q11.2 |
| Protein Type | Enzyme |
| Target Class | Enzyme |
| Function | Small molecule inhibitors of transglutaminase enzymatic activity |
| Mechanism of Action | Small molecule inhibitors of transglutaminase enzymatic activity |
| Primary Expression | various tissues, including the central nervous system, where it is particularly abundant in neurons and glial cells |
| Subcellular Localization | including the cytoplasm, nucleus, mitochondria, and plasma membrane. The protein exhibits remarkable functional versatil |
| Druggability | Medium (0.49) |
| Clinical Stage | Phase II |
| Molecular Weight | 77 kDa |
| Amino Acids | 687 aa |
| Pathways | Autophagy, G Protein Signaling, Histone Modification, neuronal differentiation |
| UniProt ID | A2A2A0 |
| Ensembl ID | ENSG00000198959 |
| GeneCards | TGM2 |
| Human Protein Atlas | TGM2 |
| Associated Diseases | ALS, Aging, Alzheimer, Alzheimer'S Disease |
| Known Drugs/Compounds | Cystamine Dihydrochloride, Urolithin A, organophosphates |
| Interactions | GPNMB, HMGB1, C1Q, APP, S100B, STAT1 |
| SciDEX Target | View Target Profile (5 clinical trials) |
| SciDEX Hypotheses | Transglutaminase-2 Cross-Linking Inhibition Strate Low Complexity Domain Cross-Linking Inhibition |
| KG Connections | 807 knowledge graph edges |
| Databases | GeneCardsNCBI GeneHPASTRING |